Overview

A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum

Status:
Terminated
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the long-term safety of gevokizumab in treating active PG ulcers
Phase:
Phase 3
Details
Lead Sponsor:
XOMA (US) LLC